{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:01:03Z","timestamp":1785481263638,"version":"3.56.0"},"reference-count":15,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biopharmaceutical Statistics"],"DOI":"10.1080\/10543406.2026.2703579","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:55:11Z","timestamp":1785480911000},"page":"1-16","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["A phase II, seamless single-arm to two-arm Bayesian design for a time-to-event endpoint"],"prefix":"10.1080","author":[{"given":"Yun","family":"Qing","sequence":"first","affiliation":[{"name":"Novartis Pharmaceuticals Corporation","place":["East Hanover, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruitao","family":"Lin","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"e_1_3_4_2_1","unstructured":"American Cancer Society. 2026. Key statistics for lung cancer. https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/about\/key-statistics.html"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.1980"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.6030\/1939-067X-3.1.8"},{"key":"e_1_3_4_5_1","unstructured":"FDA. 2019. Demonstrating substantial evidence of effectiveness for human drug and biological products guidance for industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/demonstrating-substantial-evidence-effectiveness-human-drug-and-biological-products"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.2307\/2530297"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.184"},{"issue":"23","key":"e_1_3_4_8_1","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn L","year":"2018","unstructured":"Horn L et al. 2018. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. NEJM Evid. 379(23):2220\u20132229.","journal-title":"NEJM Evid"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.2307\/2531910"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.197"},{"key":"e_1_3_4_11_1","unstructured":"ProjectOptimusFDA. 2024. Project optimus: reforming the dose optimization and dose selection paradigm in oncology. https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-optimus"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1214\/15-BA988"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/0962280215625681"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.2005"},{"key":"e_1_3_4_15_1","unstructured":"Stan Development Team. 2025. Rstan: the R interface to Stan [R package version 2.32.7]. https:\/\/mc-stan.org\/"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.1654"}],"container-title":["Journal of Biopharmaceutical Statistics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10543406.2026.2703579","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/10543406.2026.2703579","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10543406.2026.2703579","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:55:15Z","timestamp":1785480915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10543406.2026.2703579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":15,"alternative-id":["10.1080\/10543406.2026.2703579"],"URL":"https:\/\/doi.org\/10.1080\/10543406.2026.2703579","relation":{},"ISSN":["1054-3406","1520-5711"],"issn-type":[{"value":"1054-3406","type":"print"},{"value":"1520-5711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=lbps20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=lbps20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-01-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}